MA32323B1 - Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques - Google Patents

Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques

Info

Publication number
MA32323B1
MA32323B1 MA33378A MA33378A MA32323B1 MA 32323 B1 MA32323 B1 MA 32323B1 MA 33378 A MA33378 A MA 33378A MA 33378 A MA33378 A MA 33378A MA 32323 B1 MA32323 B1 MA 32323B1
Authority
MA
Morocco
Prior art keywords
disorders
preparation
sulfonamides
heterocyclic
oxadiazolone
Prior art date
Application number
MA33378A
Other languages
Arabic (ar)
English (en)
Inventor
Stefanie Keil
Matthias Urmann
Wolfgang Wendler
Maike Glien
Hans Matter
Eugen Falk
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32323B1 publication Critical patent/MA32323B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, des procédés pour leur préparation et leur utilisation comme médicaments. La présente invention concerne des sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone et leurs sels physiologiquement acceptables et leurs dérivés physiologiquement fonctionnels présentant une activité agoniste ppardelta ou ppardelta et pparalpha. L'invention concerne plus précisément des composés de formule i, dans laquelle les radicaux sont tels que définis, et leurs sels physiologiquement acceptables et des procédés pour leurs préparations. Les composés sont appropriés pour le traitement et/ou la prévention de troubles du métabolisme des acides gras et de troubles dans l'utilisation du glucose ainsi que de troubles dans lesquels l'insulino-résistance est impliquée et de troubles de démyélinisation et autres troubles neurodégénératifs du système nerveux central et périphérique.
MA33378A 2008-06-09 2010-11-30 Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques MA32323B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290572 2008-06-09
PCT/EP2009/003648 WO2009149820A1 (fr) 2008-06-09 2009-05-22 Sulfonamides n-hétérocycliques annelés avec groupement de tête oxadiazolone, procédés pour leur préparation et leur utilisation comme médicaments

Publications (1)

Publication Number Publication Date
MA32323B1 true MA32323B1 (fr) 2011-05-02

Family

ID=40219356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33378A MA32323B1 (fr) 2008-06-09 2010-11-30 Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques

Country Status (19)

Country Link
US (2) US8329725B2 (fr)
EP (1) EP2288604B1 (fr)
JP (1) JP2011523664A (fr)
KR (1) KR20110023855A (fr)
CN (1) CN102056921A (fr)
AR (1) AR072013A1 (fr)
AU (1) AU2009256982A1 (fr)
BR (1) BRPI0914978A2 (fr)
CA (1) CA2727373A1 (fr)
CL (1) CL2009001365A1 (fr)
IL (1) IL209805A0 (fr)
MA (1) MA32323B1 (fr)
MX (1) MX2010013264A (fr)
NZ (1) NZ589694A (fr)
RU (1) RU2010154279A (fr)
TW (1) TW201011012A (fr)
UY (1) UY31872A (fr)
WO (1) WO2009149820A1 (fr)
ZA (1) ZA201007679B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667545A1 (fr) * 2006-10-25 2008-05-02 Neurosearch A/S Composes de type oxadiazole et thiadiazole et leur utilisation comme modulateurs des recepteurs nicotiniques de l'acetylcholine
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012064744A2 (fr) * 2010-11-08 2012-05-18 Lycera Corporation Tétrahydroquinoline et composés bicycliques associés pour l'inhibition de l'activité rorγ et le traitement de maladies
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2847198B1 (fr) 2012-05-08 2016-12-14 Lycera Corporation Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de ror-gamma et dans le traitement d'une maladie
KR20150007300A (ko) 2012-05-08 2015-01-20 머크 샤프 앤드 돔 코포레이션 Ror감마 활성의 억제를 위한 테트라히드로나프티리딘 및 관련 비시클릭 화합물 및 질환의 치료
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
WO2015095788A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Benzoxazine carbamates de 2-acylamidométhyle et de sulfonylamidométhyle pour l'inhibition de l'activité du rorgamma et le traitement d'une maladie
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015171558A2 (fr) 2014-05-05 2015-11-12 Lycera Corporation Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
EP3140291A4 (fr) 2014-05-05 2018-01-10 Lycera Corporation Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies
AU2016219183B2 (en) 2015-02-11 2020-06-11 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA3002846A1 (fr) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Composes pyrazoles bicycliques substitues en tant qu'inhibiteurs de rorgammat et leurs utilisations
CA3002850A1 (fr) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Composes indazole substitues utilises en tant qu'inhibiteurs de rorgammat et utilisations associees
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513935A (ja) * 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
DE10222034A1 (de) 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
US20060258683A1 (en) 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE10335450A1 (de) 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
SG138623A1 (en) 2004-04-01 2008-01-28 Aventis Pharmaceuticals Inc Us Use of ppr delta agonists for treating demyelinating diseases
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP1932843A1 (fr) * 2006-12-14 2008-06-18 sanofi-aventis Dérivés de sulfonyl-phenyl-2H(1,2,4) oxadiazole-5-one, procédés de préparation de ceux-ci et leur usage sous forme de médicaments
ES2427968T3 (es) * 2008-07-14 2013-11-05 Santen Pharmaceutical Co., Ltd Nuevos derivados de indol que tienen un grupo carbamoilo, un grupo ureido y un grupo oxi sustituido
WO2010090009A1 (fr) * 2009-02-05 2010-08-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivés d'indoline
ES2481873T3 (es) * 2010-05-12 2014-07-31 Abbvie Inc. Pirrolopiridina y pirrolopirimidina inhibidores de quinasas

Also Published As

Publication number Publication date
WO2009149820A1 (fr) 2009-12-17
MX2010013264A (es) 2011-02-25
US20110207738A1 (en) 2011-08-25
US8329725B2 (en) 2012-12-11
CN102056921A (zh) 2011-05-11
NZ589694A (en) 2012-05-25
US20120122853A1 (en) 2012-05-17
EP2288604B1 (fr) 2014-01-08
ZA201007679B (en) 2011-07-27
AU2009256982A1 (en) 2009-12-17
TW201011012A (en) 2010-03-16
CL2009001365A1 (es) 2010-11-05
US8946212B2 (en) 2015-02-03
EP2288604A1 (fr) 2011-03-02
KR20110023855A (ko) 2011-03-08
BRPI0914978A2 (pt) 2015-10-27
JP2011523664A (ja) 2011-08-18
UY31872A (es) 2010-01-29
AR072013A1 (es) 2010-07-28
CA2727373A1 (fr) 2009-12-17
IL209805A0 (en) 2011-02-28
RU2010154279A (ru) 2012-07-20

Similar Documents

Publication Publication Date Title
MA32323B1 (fr) Sulfonamides n-hétérocycliques annelés avec un groupe de tête oxadiazolone, procédés pour leur préparation et leur utilisation en tant qu'agents pharmaceutiques
MY148982A (en) Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
US9926299B2 (en) Inhibitors of bruton's tyrosine kinase
TN2009000138A1 (fr) Biaryl-ether-urees
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
BRPI0509517A (pt) derivados de oxadiazolona como agonistas de ppar delta
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
JP6636060B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
MA27741A1 (fr) Derives diarylcycloalkyles , procede pour leur production, et leur utilisation en tant que medicaments
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
CN112384220A (zh) sGC刺激剂治疗线粒体障碍的用途
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
TW200500349A (en) Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals
MA29812B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques
WO2007039174A3 (fr) [1,3,4]-thiadiazol-2-yl-amides bicycliques de l'acide aryl-sulfonique, leurs procedes de preparation, et leur utilisation en tant que substances pharmaceutiques
MY148883A (en) Derivatives of 2-aminothiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
US9796722B1 (en) Hepatitis B viral assembly effectors
US20220047587A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
MY140251A (en) Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals